Ospemifene (Osphena; Shionogi & Co., Florham
Park, NJ) is a selective estrogen receptor modulator
recently approved for the treatment of dypareunia in
postmenopausal women with vulvar vaginal atrophy.
However, there are potential concerns with ospemifene.
It should not be prescribed for women with
hormone-regulated cancers (ie, breast cancers); may
cause endometrial hyperplasia; and, like other selective
estrogen receptor modulators, there is a risk of
thrombotic events